Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Liquidia Corp (LQDA)

Liquidia Corp (LQDA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Liquidia Corporation to Present at Upcoming Healthcare Investment Conferences GlobeNewswire - Mon Nov 3, 7:00AM CST

MORRISVILLE, N.C., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company revolutionizing care for patients with challenging respiratory and vascular diseases,...

LQDA : 34.53 (+2.55%)
Liquidia Corporation Reports Third Quarter 2025 Financial Results and Provides Corporate Update GlobeNewswire - Mon Nov 3, 5:30AM CST

Recorded $51.7 million in net product sales of YUTREPIA™ as launch momentum continues Achieved profitability in the first full quarter of YUTREPIA sales More than 2,000 unique patient prescriptions...

LQDA : 34.53 (+2.55%)
Liquidia Corporation to Report Third Quarter 2025 Financial Results on November 3, 2025 GlobeNewswire - Mon Oct 27, 7:30AM CDT

MORRISVILLE, N.C., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, announced...

LQDA : 34.53 (+2.55%)
Bank of America Securities Sticks to Their Buy Rating for Liquidia Technologies (LQDA) Tipranks - Fri Oct 10, 6:08AM CDT

In a report released today, Jason Gerberry from Bank of America Securities maintained a Buy rating on Liquidia Technologies, with a price target of $37.00. The company’s shares closed yesterday at $24.08.Elevate...

LQDA : 34.53 (+2.55%)
Liquidia Corporation to Host R&D Day in New York City on October 28, 2025 GlobeNewswire - Tue Oct 7, 5:30AM CDT

MORRISVILLE, N.C., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, today...

LQDA : 34.53 (+2.55%)
Liquidia to Present Clinical Data from ASCENT Trial at the CHEST 2025 Annual Meeting GlobeNewswire - Mon Sep 29, 7:30AM CDT

MORRISVILLE, N.C., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary diseases, announced...

LQDA : 34.53 (+2.55%)
Liquidia Announces Poster Presentations at the Pulmonary Hypertension Professional Association (PHPN) Symposium GlobeNewswire - Thu Sep 11, 7:30AM CDT

MORRISVILLE, N.C., Sept. 11, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease,...

LQDA : 34.53 (+2.55%)
Liquidia Corporation to Present at the 2025 Wells Fargo Healthcare Conference GlobeNewswire - Wed Aug 27, 7:30AM CDT

MORRISVILLE, N.C., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that members of the company’s executive leadership team will be providing an update on the...

LQDA : 34.53 (+2.55%)
Liquidia Corporation Reports Second Quarter 2025 Financial Results and Provides Corporate Update GlobeNewswire - Tue Aug 12, 5:30AM CDT

YUTREPIA™ surpasses 900 unique patient prescriptions and 550 patient starts within 11 weeks after approval to treat PAH and PH-ILD Positive interim data from ASCENT trial reinforces YUTREPIA’s tolerability...

LQDA : 34.53 (+2.55%)
Liquidia Corporation to Report Second Quarter 2025 Financial Results on August 12, 2025 GlobeNewswire - Tue Aug 5, 7:30AM CDT

MORRISVILLE, N.C., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease,...

LQDA : 34.53 (+2.55%)

Barchart Exclusives

As Google Launches Gemini 3 Flash, Should You Buy, Sell, or Hold GOOGL Stock? Barchart - 1 hour ago
Alphabet looks like a buy, with Gemini 3 Flash riding an AI data‑center boom, Google Cloud and Gemini winning large enterprise and infrastructure deals, and Wall Street assigning a "Strong Buy" rating. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot